The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer

Regulation by hypoxia may underlie the expression of vascular endothelial growth factor in bladder cancer. We have compared the distribution of vascular endothelial growth factor mRNA with a hypoxia marker, carbonic anhydrase 9 (CA IX), vascular endothelial growth factor mRNA was analysed by in situ hybridisation and CA IX by immunochemistry in 22 cases of bladder cancer. The relationship of microvessels to the distribution of CA IX was determined. In a separate series of 49 superficial tumours, CA IX immunostaining was compared with clinico-pathological outcome. In superficial and invasive disease there was overlap in the expression of vascular endothelial growth factor and CA IX, CA IX being more widespread. Both were expressed predominantly on the luminal surface, and surrounding areas of necrosis (invasive tumours). Expression of both factors was greater in superficial disease. Expression was absent within ~80 μm of microvessels. Unlike vascular endothelial growth factor, CA IX did not predict outcome in superficial disease. Differential responses to reoxygenation provide one explanation: vascular endothelial growth factor mRNA declined rapidly, while CA IX expression was sustained for >72 h. Expression of vascular endothelial growth factor mRNA in bladder tumours is consistent with hypoxic regulation and suggests differential regulation in superficial vs invasive disease. The expression of CA IX on the luminal surface justifies investigation of its utility as a therapeutic target/prognostic indicator.

Keywords: bladder neoplasms; angiogenic factors; carbonic acid; cell hypoxia

Tumour growth and metastasis are dependent upon angiogenesis (Folkman, 1990). VEGF (vascular endothelial growth factor) is a key regulator of this process (Ferrara and Davis-Smyth, 1997). Expression of VEGF is an indicator of stage and outcome in a number of tumour types and functional studies have confirmed its central role in angiogenesis and tumour growth (Zhang et al, 1995; Borgstrom et al, 1998). Previously we demonstrated that expression of VEGF mRNA varies widely in human superficial bladder cancer and that the level of expression is predictive of relapse and stage progression (Crew et al, 1997). The mechanisms by which some superficial tumours express VEGF mRNA at low levels and others considerably higher (up to 345-fold more) remain undetermined. An understanding of these mechanisms may shed light on factors influencing a more angiogenic and therefore more aggressive phenotype, and could provide new therapeutic or prognostic approaches. Interestingly there are differences between superficial and invasive tumours in this regard. For example, expression of the angiogenic factor thymidine phosphorylase (TP) is significantly higher in invasive than in superficial bladder tumours (O’Brien et al, 1995). In contrast, expression of VEGF mRNA is four-fold higher in superficial than in invasive tumours though expression of VEGF protein does not differ (O’Brien et al, 1995). This is indicative of differential regulation at the translational level and we have shown that expression of the eukaryotic initiation factor-4E (eIF-4E) correlates with VEGF protein:mRNA ratios in bladder tumours (Crew et al, 2000).

The regulation of VEGF by hypoxia has received considerable attention. Tumour hypoxia is associated with rapid proliferation, increased risk of metastasis and poor outcome (Brizel et al, 1996). Regulation of gene expression by hypoxia may explain these effects. Genes regulated by hypoxia include those that facilitate anaerobic metabolism of glucose (Firth et al, 1994; Ebert et al, 1996), and genes that enhance vascularity and oxygen delivery such as VEGF (Schweiki et al, 1992). The transcription factor complexes HIF-1 (hypoxia inducible factor 1) and HIF-2 have emerged as key mediators of the hypoxic upregulation of these genes (Semenza, 1999). Hypoxia is usually associated with acidic pH which may promote tumour growth (Martinez-Zaguilan et al, 1996). Carbonic anhydrases are important for regulation of pH and we demonstrated recently that the tumour associated carbonic anhydrase 9 (CA9) is tightly regulated by the HIF-1 pathway (Wykoff et al, 2000). (CA9 refers to the carbonic anhydrase 9 gene including any genomic sequence and mRNA, CA IX refers to the corresponding protein). CA9 is induced strongly by hypoxia in a number of tumour cell lines and the CA9 gene has a HIF-1 hypoxia response
element (HRE) immediately 5’ to its transcriptional start site. Expression of CA IX was compared with that of the bioreductive hypoxia marker pimonidazole in a series of bladder transitional cell carcinomas. The distribution of the two factors was strikingly similar although staining for CA IX was less extensive. Both CA IX and pimonidazole were detected at the luminal surface of papillary tumours and around areas of necrosis.

Because pathways of both pH regulation (CA9) and angiogenesis (VEGF) are regulated by hypoxia, we have compared the expression patterns of CA IX and VEGF in superficial and invasive bladder cancers. Expression of VEGF was evaluated at the level of mRNA for two reasons. First, VEGF protein is secreted and therefore VEGF mRNA is a superior marker of the localisation of VEGF production and regulation. Second, knowledge of the localisation of the mRNA might facilitate understanding of the mechanisms of VEGF mRNA upregulation in bladder cancer, which have not been studied previously.

We demonstrate that VEGF mRNA is expressed most strongly on the luminal surface of bladder tumours, and surrounding areas of necrosis. This expression co-localises with areas of tumour hypoxia as defined by expression of CA IX in both superficial and invasive bladder tumours. We also show that expression of CA IX is greater in superficial than invasive tumours, consistent with previous observations on the expression of VEGF mRNA (O’Brien et al, 1995). These observations highlight differences between superficial and invasive bladder cancer, suggesting that different pathways may regulate angiogenesis in superficial and invasive disease with the possibility that hypoxia is the driver of angiogenesis in papillary tumours.

MATERIALS AND METHODS

Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue specimens collected by standard surgical oncology procedures were obtained from the Pathology Department, John Radcliffe Hospital, Oxford, UK. Samples of normal bladder were taken from cadaveric organ donors at the time of nephroureterectomy. CA IX immunostaining using monoclonal antibody M75 was as described (Wykoff et al, 2000). Slides were viewed by two observers (K Turner and P Watson). The CA IX score was derived from the product of (i) the percentage of tumour cells staining for CA IX and (ii) the average intensity of that staining on a scale of 1 (least intense) to 3. M75 antibody was from Pastorek (Pastorek et al, 1994).

Double staining for CA IX and CD34

CA IX immunostaining was as described with omission of counterstaining (Wykoff et al, 2000). Sections were then incubated with 1:100 MoAb QBEnd10 (DAKO) (30 min) and then with goat anti-mouse IgG (PO447, DAKO) (30 min) followed by APAAP (1:100 MoAb QBEnd10 (DAKO) (30 min) followed by APAAP (30 min). The last two steps were repeated twice with 10 min incubations. Visualisation was by New Fuchsian Red substrate (DAKO).

In situ mRNA hybridisation

Specific localisation of VEGF mRNA was accomplished by in situ hybridisation using an antisense riboprobe as described (Wykoff et al, 2000). CA IX and VEGF mRNA were studied in serial tissue sections. In the majority of cases CA IX expression was more widespread than expression of VEGF mRNA. For this reason, the percentage of the tumour expressing VEGF mRNA that was also positive for CA IX was quantified in each section. Sections were viewed by two observers (K Turner and P Watson) and a consensus reached.

Effect of reoxygenation on hypoxically induced CA IX protein/VEGF mRNA tissue culture

The A549 lung carcinoma cell line was obtained from ECACC (European Collection of Animal Cell Cultures, UK). Cells were grown in DMEM (Sigma) supplemented with 10% foetal calf serum (Globepharm), 1-glutamine (2 mM), penicillin (50 IU ml⁻¹), and streptomycin sulphate (50 μg ml⁻¹). Studies of gene expression were performed on cells approaching confluence in normal growth medium. Parallel incubations were performed on aliquots of cells in normoxia (humidified air with 5% CO₂) and hypoxia. Hypoxic conditions were generated in a Napec 7001 incubator (Precision Scientific) with 0.1% O₂, 5% CO₂, and balance N₂. Re-oxygenation experiments were performed by exposure of cells to hypoxia for 16 h followed by a return to normoxia for the indicated time.

RNA analysis

Total RNA was extracted by a modified acid/phenol/chloroform method (RNAzol B; Cinna/Biotech Laboratories), dissolved in hybridisation buffer (80% formamide, 40 mM PIPES, 400 mM sodium chloride, and 1 mM EDTA, pH 8) and analysed by RNase protection assay (RPA). RPAs for vascular endothelial growth factor-A (VEGF-A) and CA9 were performed using 32P-labelled RNA probes transcribed using SP6 RNA polymerase from the previously described DNA templates (Maxwell et al, 1999; Wykoff et al, 2000). RPAs were performed on 30 μg total RNA using an internal control assay for U6 small nuclear RNA as described (Maxwell et al, 1999).

Cell lysis and immunoblotting

Whole cell protein extracts were prepared from tissue culture cells by 10 s homogenisation in denaturing conditions as described (Wiesener et al, 1998). For Western analysis, aliquots were separated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes. CA IX was detected using the mouse monoclonal anti-human CA IX antibody M75 (1:50) as described (Pastorekova et al, 1992). HRP-conjugated goat-anti-mouse immunoglobulin (DAKO) (1:2000) was applied for 1 h at room temperature (RT). ECL Plus (Amersham Pharmacia) was used for visualisation.

RESULTS

Expression of VEGF mRNA in bladder cancer

Expression of VEGF mRNA was examined by in situ hybridisation in 22 cases of bladder cancer selected to represent the range of stage and grade in human bladder tumours (Table 1), and in two samples of normal bladder. Expression of a control mRNA (β-actin) was verified in each case as a marker of mRNA preservation (data not shown). Neither of the samples of normal bladder showed any expression of VEGF mRNA (data not shown). There was considerable inter-tumour variation in VEGF with no expression detected in four cases (one case of isolated carcinoma in situ (CIS), two TaG1 tumours, and one T3G3 tumour). In the remaining cases expression was most intense on the luminal surface of tumours. This expression was patchy, with areas of strong and weak luminal expression within the same resected chip. Enhanced luminal expression was particularly marked in superficial tumours: intense staining of the outer half of the transitional cell epithelium was typical (approximately 50 μm from luminal surface to core) (Figure 1). Increased luminal expression was also noted in all chips of invasive tumour that contained surface epithelium. However, this staining was substantially less intense and widespread than in superficial tumours (Figure 2). In several cases of invasive...
Expression of hypoxia inducible genes in bladder cancer

KJ Turner et al

Molecular and Cellular Pathology

British Journal of Cancer (2002) 86, 1276–1282

Expression of CA IX protein and VEGF mRNA in human bladder cancer

| Patient | Tumour stage/grade | VEGF in situ hybridisation | CA IX immunostaining | > 50% overlap |
|---------|-------------------|---------------------------|----------------------|--------------|
| 1       | CIS               | -ve                       | -ve                  | na           |
| 2       | Ta G1             | -ve                       | luminal              | na           |
| 3       | Ta G1             | -ve                       | luminal              | na           |
| 4       | Ta G2             | luminal                   | luminal              | y            |
| 5       | T1 G1             | luminal                   | luminal              | y            |
| 6       | T1 G2             | luminal                   | luminal              | y            |
| 7       | T1 G2             | luminal                   | luminal              | y            |
| 8       | T1 G2             | luminal                   | luminal              | y            |
| 9       | T1 G2             | luminal                   | luminal              | y            |
| 10      | T2 G2             | luminal, and              | luminal, and         | y            |
|         |                   | perinecrotic              | perinecrotic         |              |
| 11      | T2 G2             | luminal and               | luminal and          | y            |
|         |                   | invasive tumour           | invasive tumour      |              |
| 12      | T2 G3             | luminal                   | luminal              | y            |
| 13      | T2 G3             | luminal                   | luminal              | y            |
| 14      | T2 G3             | luminal, and              | luminal but          | n            |
|         |                   | perinecrotic              | sparse               |              |
| 15      | T2 G2, CIS in separate biopsy | perinecrotic | perinecrotic         | y            |
| 16      | T2 G2, CIS in separate biopsy | CIS — ve     | CIS — ve            | y            |
| 17      | T2 G2             | CIS weakly positive       | CIS weakly positive  |              |
|         |                   | perinecrotic              | perinecrotic         |              |
| 18      | T2 G3             | luminal and               | luminal and          | y            |
|         |                   | perinecrotic              | perinecrotic         |              |
| 19      | T2 G3             | invasive tumour           | invasive tumour      | y            |
| 20      | T2 G3, CIS in separate biopsy | luminal and | luminal and         | y            |
|         |                   | perinecrotic              | perinecrotic         |              |
| 21      | T3 G3             | -ve                       | -ve                  | na           |
| 22      | T4 G3, CIS in separate biopsy | luminal, CIS | luminal, CIS        | y            |

Table 1

In a series of 22 human bladder tumours of a range of stage and grade the location of expression of VEGF was assessed by in situ hybridisation of mRNA. In serial sections expression of CA IX was assessed by immunochemistry using monoclonal antibody M75. In each case the percentage of the tumour expressing VEGF mRNA that was also positive for CA IX (i.e. the overlap) was quantified. y=yes; n=no; na=not applicable.

tumour, in addition to luminal expression, there was enhanced expression of VEGF within the invasive portion of the tumour. This expression was observed primarily around areas of necrosis (Figure 2). Of the four cases of invasive bladder cancer in which there was CIS in a separate biopsy, the CIS did not express VEGF in two cases and was weakly positive in the remaining two cases.

Expression of CA IX

CA IX expression was evaluated by immunohistochemistry in the same 22 cases on serial sections. In 17 out of 18 cases in which VEGF mRNA was detected, at least 50% of the areas that expressed VEGF mRNA also expressed CA IX. Furthermore, the distribution of CA IX and VEGF expression was strikingly similar (Figures 1 and 2). Like VEGF mRNA, CA IX was expressed maximally on the luminal surface of tumours and around regions of necrosis in invasive tumours. In addition, whilst both superficial and invasive tumours showed luminal enhancement, this was much more marked in superficial tumours. Expression of CA IX in the sections of CIS from patients with invasive tumours matched that of VEGF; CA IX was not detected in the normal bladder specimens, nor was it detected in samples from the patient with isolated CIS.

In addition to these 22 cases, CA IX immunostaining was performed on a further five cases of isolated CIS, three normal bladders and four normal ureters. Of these, one case of CIS showed very weak luminal staining, but the remainder of the CIS cases and all sections of normal urothelium were negative for CA IX expression. In summary, in a total of 10 cases of CIS, immunostaining for CA IX was weak in three, and absent in seven.

Relationship of CA IX to microvessels

In order to elucidate factors that might influence the expression of CA IX in bladder cancer, we examined the relationship between expression of CA IX and tumour microvessels. The distribution of CD 34 staining (as a marker of blood vessels) was compared to that of CA IX staining in the same sections for a subset of cases (52 vessels were assessed in 12 different cases, Figure 3). In superficial and invasive tumours, CA IX expression was typically detected in regions of the tumour that were a mean distance of 80 μm from a blood vessel (standard deviation=44 μm).

Relationship of CA IX expression in superficial bladder cancer to other clinical and prognostic factors

We have demonstrated previously that VEGF mRNA expression on RNase protection was predictive of recurrence and stage progression in a series of 59 superficial bladder tumours (Ta/T1, G1/G2) (Crew et al, 1997). Given the association between CA IX and VEGF expression, we aimed to establish whether CA IX expression was also predictive of outcome in these cases. Therefore, sections from 49 of these previously studied cases were stained for CA IX and expression was scored semi-quantitatively (range=0–225, median=30, cases were split into 'low' CA IX (i.e. score <median (n=22), and 'high' CA IX (i.e. score >median (n=27)). Comparisons were made between CA IX expression and other factors that we had determined previously including expression of VEGF mRNA (by RNase protection), tumour grade, risk of recurrence, time to recurrence, and risk...
of stage progression (Table 2). Although we had observed concordance of the focal staining pattern in superficial tumours, the total level of VEGF mRNA as assessed by RNAse protection did not correlate statistically with the CA IX score in these cases. No significant associations were found between CA IX staining and any other of these parameters when assessed by both continuous and cutpoint analysis.

Temporal relationship of CA IX/VEGF expression to hypoxia and reoxygenation

Though there was striking overlap in the expression of CA IX and VEGF, there were differences in the extent of the expression of these two factors. Specifically, CA IX was generally expressed over a greater area of the tumour than VEGF mRNA, and VEGF but not...
Expression of hypoxia inducible genes in bladder cancer

KJ Turner et al

CA IX was predictive of time to recurrence and risk of stage progression in Ta/T1 disease. We therefore investigated any differences in regulation that might underlie these observations. In particular we investigated the temporal relationship between expression of CA IX/VEGF and hypoxia and reoxygenation. To our knowledge, there are no currently available cell lines derived from superficial human bladder tumours. Previously we had been unable to detect hypoxic induction of both VEGF and CA9, was chosen for these studies. Interestingly, whilst CA9 mRNA and CA IX protein, and VEGF mRNA were induced by hypoxia, they differed markedly in their response to reoxygenation (Figure 4). Detection of CA IX protein remained constant for at least 72 h, but both CA9 mRNA and VEGF mRNA declined rapidly, reaching normoxic levels of expression within 8 h.

DISCUSSION

Angiogenesis plays a key role in the pathogenesis of bladder cancer: microvessel density is a prognostic indicator in invasive bladder cancer (Bochner et al., 1995; Jaeger et al., 1995), expression of the angiogenic factors bFGF (basic fibroblast growth factor), TGFβ (transforming growth factor β), midkine, and HGF (hepatocyte growth factor) is elevated in patients with bladder cancer (reviewed in Jones and Fujiyama, 1999) and VEGF expression is predictive of stage progression and relapse in superficial tumours (Crew et al., 1997). Current attention is focused on the upstream events that govern expression of angiogenic mediators. Hypoxia has emerged as a potent stimulus in this regard, with hypoxia inducible transcription factors regulating many aspects of this hypoxic response, including expression of VEGF. The activity of the HIF pathway can also be modulated by genetic influences such as mutations in the VHL gene and other oncogenes (Maxwell et al., 1999), and by growth factors (Semenza, 2000).

In this study we have investigated the relationship between expression of VEGF and CA IX, having shown previously that...

Table 2 Relationship of CA IX expression in human bladder cancer to other clinicopathological parameters

| CA IX Score   | Median (range) | Grade (%) | Recurrence at 6 months (%) | Time to recurrence in months Mean (s.d.) | Progression (% progressed) | Mean time to progression in months Mean (s.d.) |
|---------------|----------------|-----------|----------------------------|------------------------------------------|---------------------------|---------------------------------------------|
| Low           | 62.5 (4–242)   | 27        | 55                         | 6.8 (6.7)                                | 27                        | 9.3 (5.8)                                   |
| High          | 91 (1–345)     | 19        | 48                         | 5.7 (4.9)                                | 19                        | 6.4 (3.5)                                   |

Expression of CA IX was determined in a series of 49 superficial (Ta/T1, G1/G2) bladder tumours by immunohistochemistry using antibody M75. The CA IX score was derived from the product of (i) the percentage of tumour cells staining for CA IX and (ii) the average intensity of that staining on a scale of 1 (least intense) to 3. Cases were split into 'low' CA IX (i.e. score < median (n=22)) and 'high' CA IX (i.e. score ≥ median (n=27)). Comparisons were made between CA IX expression and other factors that we had determined previously including expression of VEGF mRNA (by RNAse protection), tumour grade, risk of recurrence, time to recurrence, and risk of stage progression. There were no significant differences in the variables between tumours with high and low CA IX scores. *Arbitrary units.

British Journal of Cancer (2002) 86(8), 1276–1282 © 2002 Cancer Research UK
CA 9 is upregulated by HIF. We demonstrate that expression of VEGF mRNA localises to areas of the tumour that also express CA IX in both superficial and invasive bladder cancers. These observations suggest that expression of VEGF in human bladder cancer is determined by tumour hypoxia and may be mediated via the HIF pathway.

Expression of both VEGF and CA IX was most intense on the luminal surface of tumours. Malignant transitional epithelium is many times thicker than transitional cell epithelium in normal bladder. The reduced oxygen tension that is associated with this increased distance from vessels may enhance expression of VEGF. Increasingly, superficial and invasive bladder cancers are regarded as distinct pathological entities and a two-pathway model for bladder tumour development has been proposed (see Lee and Droller, 2000 for review). In keeping with this, superficial and invasive bladder tumours differ in their expression of angiogenic mediators. For example, expression of VEGF is four-fold higher in superficial tumours than in invasive tumours but expression of thymidine phosphorylase is 33 times higher in invasive tumours (O’Brien et al., 1995). In concordance with these results, we show here that expression of VEGF mRNA is more widespread in superficial tumours than in invasive tumours.

The localisation, shown here for the first time, of VEGF mRNA on the luminal surface of bladder tumours explains the strong relationship we have found previously between urinary and tumour VEGF protein, and the relationship of urinary VEGF to recurrence (Crew et al., 1999). Expression of CA IX/VEGF mRNA at the luminal surface of invasive tumours was markedly less than that on the luminal surface of superficial tumours, even in regions of equivalent distance from vessels. In addition, expression of CA IX/VEGF mRNA was observed around areas of necrosis in invasive tumours, a phenomenon that we have observed in tumours of the breast, ovary, and head and neck (Wykoff et al., 2000). This perinecrotic expression of CA IX/VEGF was also markedly less intense than that observed on the luminal surface of superficial tumours, even though microenvironmental hypoxia is the likely precipitant. These data therefore suggest that there is relatively less activation of hypoxia regulated transcription pathways in invasive tumours. This apparent difference between the two tumour types adds to the evidence that superficial and invasive bladder cancer represent different disease processes.

Support for this hypothesis comes from our observations in CIS, which is currently regarded as a progenitor of the invasive rather than superficial phenotype (Lee and Droller, 2000). Like invasive

**REFERENCES**

Bochner BH, Cote RJ, Weidner N, Groschen S, Chen SC, Skinner DG, Nichols PW (1995) Angiogenesis in bladder cancer: relationship between microvesel density and tumor prognosis. J Natl Cancer Inst 87: 1603–1612

Borgstrom P, Bourdon MA, Hillan KJ, Sirimaraoo P, Ferrara N (1998) Neuronal nitric oxide synthase and vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate cancer microtumors in vivo. Prostate 35: 1–10

Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941–943

Creel PJ, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL (2000) Eukaryotic initiation factor-4e in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 82: 161–166

Crew JP, O’Brien T, Bicknell R, Fuggle S, Cranston D, Harris A (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161: 799–804

Crew JP, O’Brien T, Bradburn M, Fuggle S, Bicknell R, D. C, Harris AL (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281–5285

Ebert BL, Gleed J, O’Rourke JF, Bartlett SM, Poulton J, Ratcliffe PJ (1996) Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin. Biochem J 310: 799–814

Ferrara N, Davis-Smyth TD (1997) The biology of vascular endothelial growth factor. Endocr Rev 10: 4–25

Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ (1994) Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3’ enhancer. Proc Natl Acad Sci USA 91: 6496–6500

Folkman J (1990) What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 82: 4–6

Jaeger TM, Weidner N, Cwek K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR (1995) Tumour angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 154: 69–71

Jones A, Fujisawa C (1999) Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. Br J Urol 83: 533–536

Lee R, Droller MJ (2000) The natural history of bladder cancer. Urologic Clinics of North America 27: 1–13
Levy NS, Chung S, Furneaux H, Levy AP (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. *J Biol Chem* 273: 6417–6423

Martinez-Zaguilan R, Setfot EA, Setfot RE, Chu YW, Gillies RJ, Hendrix MJ (1996) Acidic pH enhances the invasive behavior of human melanoma cells. *Clin Exp Metastasis* 14: 176–186

Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* 399: 271–275

O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL (1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. *Cancer Res* 55: 510–513

Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ (1994) Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. *Oncogene* 9: 2877–2888

Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel quasi-viral agent, Ma Tu, is a two-component system. *Virology* 187: 620–626

Schweiki D, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. *Nature* 359: 843–845

Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol* 15: 551–578

Semenza GL (2000) HIF-1 and human disease: one highly involved factor. *Genes Dev* 14: 1983–1991

Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS (1993) A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. *Anticancer Res* 13: 1549–1556

Wiesener MS, Turley H, Allen WE, William C, Eckardt KU, Talks KL, Wood SM, Pugh CW, Ratcliffe PJ, Maxwell PH (1998) Induction of endothelial PAS domain protein-1 by hypoxic: Characterisation and comparison with hypoxia-inducible factor-1x. *Blood* 92: 2260–2268

Wykoff CC, Beasley NJP, Watson PW, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks K, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia inducible expression of tumor associated carbonic anhydrases. *Cancer Res* 60: 7075–7083

Zhang H-T, Craft P, Scott PFP, Ziche M, Weich HA, Harris AL, Bicknell R (1995) Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells. *J Natl Cancer Inst* 87: 213–218